Stockscreener 앱 받기
59.78
0.74%
0.43
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Is Disc Medicine Inc. stock overvalued or undervaluedEarnings Report Recommendation To Watch Now - jammulinksnews.com
Institutional Investors in Disc Medicine, Inc. (NASDAQ:IRON) See US$140m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
Why Disc Medicine Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - metal.it
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT - MSN
How many analysts rate Disc Medicine Inc. as a “Buy”Tremendous wealth creation - jammulinksnews.com
Disc Medicine's NDA Submission for Bitopertin in EPP: A High-Probability Catalyst for Value Creation - AInvest
Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 - Insider Monkey
What is the dividend policy of Disc Medicine Inc. stockMaximize gains with strategic stock entries - jammulinksnews.com
Is Disc Medicine Inc. a growth stock or a value stockGet daily expert analysis for smarter investing - jammulinksnews.com
Are Investors Undervaluing Disc Medicine, Inc. (NASDAQ:IRON) By 49%? - Yahoo Finance
How does Disc Medicine Inc. compare to its industry peersExpert Picks Watchlist For 2025 - jammulinksnews.com
How volatile is Disc Medicine Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
What are analysts’ price targets for Disc Medicine Inc. in the next 12 monthsGet ahead with breakthrough trading ideas - jammulinksnews.com
Published on: 2025-07-28 05:56:42 - jammulinksnews.com
Should I hold or sell Disc Medicine Inc. stock in 2025Invest smarter with real-time trading signals - jammulinksnews.com
When is the best time to buy Disc Medicine Inc. stockWatchlist Winner Update - metal.it
How strong is Disc Medicine Inc. company’s balance sheetBuild wealth faster with expert stock picks - jammulinksnews.com
Is Disc Medicine Inc. stock a growth or value play2x Return Forecast - metal.it
Insider Selling at Disc Medicine Inc.: A Balancing Act Between Portfolio Strategy and Investor Sentiment - AInvest
Is Disc Medicine Inc. a good long term investmentFree Stock Movement Tracking - PrintWeekIndia
Can Disc Medicine Inc. stock recover from recent declineSuperior profit margins - jammulinksnews.com
What drives Disc Medicine Inc. stock priceBreakthrough capital growth - PrintWeekIndia
10 Best Mid Cap Stocks to Buy According to Billionaires - Insider Monkey
Is Disc Medicine Inc. stock overhyped or has real potentialBreakthrough wealth creation - jammulinksnews.com
Disc Medicine Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
What analysts say about Disc Medicine Inc. stockUnrivaled growth potential - Autocar Professional
Disc Medicine’s Strategic Advancements and Regulatory Progress Drive Buy Rating - TipRanks
Disc Medicine To Seek FDA Approval For Bitopertin In EPP, A Painful Sunlight Sensitivity Disorder - Nasdaq
Disc Medicine’s (IRON) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Disc Medicine's NDA Submission for Bitopertin in EPP: A Catalyst-Driven Opportunity in a High-Unmet-Need Market - AInvest
Disc Medicine to submit NDA for bitopertin in EPP in October By Investing.com - Investing.com India
Truist Securities initiates Disc Medicine stock with Buy rating, $86 target - Investing.com Canada
Disc Medicine to submit NDA for bitopertin in EPP in October - Investing.com
Disc Medicine, Inc. Receives Positive FDA Feedback for Bitopertin NDA Submission in Erythropoietic Protoporphyria - Nasdaq
Disc Medicine Announces Positive Pre-NDA Meeting and - GlobeNewswire
Breakthrough EPP Treatment Advances: FDA Green-Lights Bitopertin NDA Filing for Rare Blood Disease - Stock Titan
2.79%
1.75%
자본화:
|
볼륨(24시간):